Targeting malignancies with disulfiram (Antabuse): Multidrug resistance, angiogenesis, and proteasome

Current Cancer Drug Targets

Volumn 11, Issue 3, 2011, Pages 332-337

  Cvek, B ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Angiogenesis; Antabuse (disulfiram); Cancer; Multidrug resistance; Non profit drug; Proteasome

Indexed keywords

ALDEHYDE DEHYDROGENASE; BORTEZOMIB; CISPLATIN; COLCHICINE; COPPER ZINC SUPEROXIDE DISMUTASE; DIETHYLDITHIOCARBAMIC ACID; DISULFIRAM; FLUOROURACIL; GELATINASE A; GELATINASE B; GLUCONATE COPPER; GLUCONATE ZINC; GLYCOPROTEIN P; I KAPPA B; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VERAPAMIL; VINBLASTINE;

ADJUVANT THERAPY; ALCOHOL CONSUMPTION; ALCOHOLISM; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; AVERSION THERAPY; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CLINICAL TRIAL; COCAINE DEPENDENCE; COLORECTAL CANCER; CYTOTOXICITY; DRUG EFFICACY; DRUG INHIBITION; FOLLOW UP; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER METASTASIS; LUNG CANCER; MANTLE CELL LYMPHOMA; MORNING DOSAGE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NEPHROTOXICITY; NONHUMAN; PATHOLOGICAL GAMBLING; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; DISULFIRAM; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 79951688311     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800911794519806     Document Type: Article

References (65)

1. Thorn, G. D.; Ludwig R. A. The dithiocarbamates and related compounds; Elsevier Publishing Company: Amsterdam - New York, 1962.
2. Eneanya, D. I.; Bianchine, J. R.; Duran, D. O.; Andresen, B. D. The actions of metabolic fate of disulfiram. Annu. Rev. Pharmacol. Toxicol. 1981, 21, 575-596.
3. Suh, J. J.; Pettinati, H. M.; Kampman, K. M.; O'Brien, C. P. The status of disulfiram: a half of a century later. J. Clin. Psychopharmacol. 2006, 26, 290-302.
4. Williams, E. E. Effects of alcohol on workers with carbon disulfide. JAMA 1937, 109, 1472.
5. Hald, J.; Jacobsen E. A drug sensitising the organism to ethyl alcohol. Lancet 1948, 252, 1001-1004.
6. Martensen-Larsen, O. Treatment of alcoholism with a sensitising drug. Lancet 1948, 252, 1004-1005.
7. Petersen, E. N. The pharmacology and toxicology of disulfiram and its metabolites. Acta Psychiatr. Scand. Suppl. 1992, 369, 7-13.
8. Johansson, B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr. Scand. Suppl. 1992, 369, 15-26.
9. Banys, P. The clinical use of disulfiram (Antabuse): a review. J. Psychoactive Drugs 1988, 20, 243-261.
10. Kristenson, H. How to get the best out of antabuse. Alcohol Alcohol 1995, 30, 775-783.
11. Borup, C.; Kaiser, A.; Jensen, E. Long-term antabuse treatment: tolerance and reasons for withdrawal. Acta Psychiatr. Scand. Suppl. 1992, 369, 47-49.
12. Keiser, M. J.; Setola, V.; Irwin, J. J.; Laggner, C.; Abbas, A. I.; Hufeisen, S. J.; Jensen, N. H.; Kuijer, M. B.; Matos, R. C.; Tran, T. B.; Whaley, R.; Glennon, R. A.; Hert, J.; Thomas, K. L.; Edwards, D. D.; Shoichet, B. K.; Roth, B. L. Predicting new molecular targets for known drugs. Nature 2009, 462, 175-181.
13. Gaval-Cruz, M.; Weinshenker, D. Mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse. Mol. Interv. 2009, 9, 175-187.
14. Mutschler, J.; Buhler, M.; Grosshans, M.; Diehl, A.; Mann, K.; Kiefer, F. Disulfiram, an option for the treatment of pathological gambling? Alcohol Alcohol. 2010, 45, 214-216.
15. Lang, J. M.; Touraine, J. L.; Trepo, C.; Choutet, P.; Kirstetter, M.; Falkenrodt, A.; Herviou, L.; Livrozet, J. M.; Retornaz, G.; Touraine, F. Randomised, double-blind, placebo-controlled trial of ditiocarb sodium ('Imuthiol') in human immunodeficiency virus infection. Lancet 1988, 332, 702-706.
16. Reisinger, E. C.; Kern, P.; Ernst, M.; Bock, P.; Flad, H. D.; Dietrich, M. Inhibition of HIV progression by dithiocarb. German DTC Study Group. Lancet 1990, 335, 679-682.
17. Hersh, E. M.; Brewton, G.; Abrams, D.; Bartlett, J.; Galpin, J.; Gill, P.; Gorter, R.; Gottlieb, M.; Jonikas, J. J.; Landesman, S. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study. JAMA 1991, 265, 1538-1544.
18. The HIV87 Study Group. Multicenter, randomized, placebo-controlled study of ditiocarb (Imuthiol) in human immunodeficiency virus-infected asymptomatic and minimally symptomatic patients. The HIV87 Study Group. AIDS Res. Hum. Retroviruses 1993, 9, 83-89.
19. Cvek, B. Failure of ditiocarb (diethyldithiocarbamate) therapy: was diet the reason? Curr. HIV Res. 2009, 7, 254.
20. Vanham, G. L.; Kestens, L.; Van Hoof, J.; Penne, G.; Colebunders, R.; Goilav, C.; Vandenbruaene, M.; el Habib, R.; Gigase, P. Immunological parameters during treatment with ditiocarb (Imuthiol). AIDS 1993, 7, 525-530.
21. Chong, C. R.; Sullivan, D. J. New uses for old drugs. Nature 2007, 448, 645-646.
22. Boguski, M. S.; Mandl, K. D.; Sukhatme, V. P. Repurposing with a difference. Science 2009, 324, 1394-1395.
23. Borchert, P.; Wattenberg, L. W. Inhibition of macromolecular binding of benzo(a)pyrene and inhibition of neoplasia by disulfiram in the mouse forestomach. J. Natl. Cancer Inst. 1976, 57, 173-179.
24. Irving, C. C.; Tice, A. J.; Murphy, W. M. Inhibition of N-n-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder cancer in rats by administration of disulfiram in the diet. Cancer Res. 1979, 39, 3040-3043.
25. Irving, C. C.; Daniel, D. S.; Murphy, W. M. The effect of disulfiram on the carcinogenicity of N-butyl-N-(3-carboxypropyl)nitro-samine in the rat. Carcinogenesis 1983, 4, 617-620.
26. Irving, C. C.; Daniel, D. S. Influence of disulfiram on the metabolism of the urinary bladder carcinogen N-butyl-N-(4-hydroxybutyl)nitrosamine in the rat. Carcinogenesis 1987, 8, 1309-1315.
27. Dufour, P.; Lang, J. M.; Giron, C.; Duclos, B.; Haehnel, P.; Jaeck, D.; Jung, J. M.; Oberling, F. Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study. Biotherapy 1993, 6, 9-12.
28. Brar, S. S.; Grigg, C.; Wilson, K. S.; Holder, W. D.; Dreau, D.; Austin, C.; Foster, M.; Ghio, A. J.; Whorton, A. R.; Stowell, G. W.; Whittall, L. B.; Whittle, R. R.; White, D. P.; Kennedy, T. P. Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. Mol. Cancer Ther. 2004, 3, 1049-1060.
29. Iljin, K.; Ketola, K.; Vainio, P.; Halonen, P.; Kohonen, P.; Fey, V.; Grafstrom, R. C.; Perala, M.; Kallioniemi, O. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin. Cancer Res. 2009, 15, 6070-6078.
30. Loo, T. W.; Clarke, D. M. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. J. Natl. Cancer Inst. 2000, 92, 898-902.
31. Sauna, Z. E.; Peng, X. H.; Nandigama, K.; Tekle, S.; Ambudkar, S. V. The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1). Mol. Pharmacol. 2004, 65, 675-684.
32. Sauna, Z. E.; Shukla, S.; Ambudkar, S. V. Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections. Mol. Biosyst. 2005, 1, 127-134.
33. Shukla, S.; Sauna, Z. E.; Prasad, R.; Ambudkar, S. V. Disulfiram is a potent modulator of multidrug transporter Cdr1p of Candida albicans. Biochem. Biophys. Res. Commun. 2004, 322, 520-525.
34. Loo, T. W.; Bartlett, M. C.; Clarke, D. M. Disulfiram metabolites permanently inactivate the human multidrug resistance P-glycoprotein. Mol. Pharm. 2004, 1, 426-433.
35. Marikovsky, M.; Nevo, N.; Vadai, E.; Harris-Cerruti, C. Cu/Zn superoxide dismutase plays a role in angiogenesis. Int. J. Cancer 2002, 97, 34-41.
36. Shiah, S. G.; Kao, Y. R.; Wu, F. Y.; Wu, C. W. Inhibition of invasion and angiogenesis by zinc-chelating agent disulfiram. Mol. Pharmacol. 2003, 64, 1076-1086.
37. Marikovsky, M.; Ziv, V.; Nevo, N.; Harris-Cerruti, C.; Mahler, O. Cu/Zn superoxide dismutase plays important role in immune response. J. Immunol. 2003, 170, 2993-3001.
38. Cho, H. J.; Lee, T. S.; Park, J. B.; Park, K. K.; Choe, J. Y.; Sin, D. I.; Park, Y. Y.; Moon, Y. S.; Lee, K. G.; Yeo, J. H.; Han, S. M.; Cho, Y. S.; Choi, M. R.; Park, N. G.; Lee, Y. S; Chang, Y. C. Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. J. Biochem. Mol. Biol. 2007, 40, 1069-1076.
39. Karin, M.; Greten, F. R. NF-B: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005, 5, 749-759.
40. Schreck, R.; Meier, B.; Mannel, D. N.; Droge, W.; Baeuerle, P. A. Dithiocarbamates as potent inhibitors of nuclear factor B activation in intact cells. J. Exp. Med. 1992, 175, 1181-1194.
41. Liu, S. F.; Ye, X.; Malik, A. B. In vivo inhibition of nuclear factor-B activation prevents inducible nitric oxide synthase expression and systemic hypotension in a rat model of septic shock. J. Immunol. 1997, 159, 3976-3983.
42. Nakanishi, C.; Toi, M. Nuclear factor-B inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 2005, 5, 297-309.
43. Wang, W.; McLeod, H. L.; Cassidy, J. Disulfiram-mediated inhibition of NF-B activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int. J. Cancer 2003, 104, 504-511.
44. Berry, J. M.; Jacobs, C.; Sikic, B.; Halsey, J.; Borch, R. F. Modification of cisplatin toxicity with diethyldithiocarbamate. J. Clin. Oncol. 1990, 8, 1585-1590.
45. Bouvet, D.; Michalowicz, A.; Crauste-Manciet, S.; Brossard, D.; Provost, K. EXAFS and IR structural study of platinum-based anticancer drugs degradation by diethyl dithiocarbamate. Inorg. Chem. 2006, 45, 3393-3398.
46. Roemeling, R. V.; Olshefski, R.; Langevin, T.; Berestka, J.; Reusch, J. J.; Reusch, J. E.; Lakatua, D.; Wick, M. R.; Hrushesky, W. J. Cisplatin chronotherapy and disulfiram rescue reduce toxicity without interfering with anticancer activity: animal findings and preliminary clinical experiences. Chronobiol. Int. 1986, 3, 55-64.
47. Verma, S.; Stewart, D. J.; Maroun, J. A.; Nair, R. C. A randomized phase II study of cisplatin alone versus cisplatin plus disulfiram. Am. J. Clin. Oncol. 1990, 13, 119-124.
48. Cen, D.; Brayton, D.; Shahandeh, B.; Meyskens, F. L.; Farmer, P. J. Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J. Med. Chem. 2004, 47, 6914-6920.
49. Suzuki, Y.; Fujii, S.; Tominaga, T.; Yoshimoto, T.; Yoshimura, T.; Kamada, H. The origin of an EPR signal observed in dithiocarbamate-loaded tissues. Copper(II)-dithiocarbamate complexes account for the narrow hyperfine lines. Biochim. Biophys. Acta. 1997, 1335, 242-245.
50. Chen, D.; Milacic, V.; Frezza, M.; Dou, Q. P. Metal complexes, their cellular targets and potential for cancer therapy. Curr. Pharm. Des. 2009, 15, 777-791.
51. Milacic, V.; Dou, Q. P. The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy. Coord. Chem. Rev. 2009, 253, 1649-1660.
52. Chen, D.; Cui, Q. C.; Yang, H.; Dou, Q. P. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res. 2006, 66, 10425-10433.
53. Orlowski, R. Z.; Kuhn, D. J. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin. Cancer Res. 2008, 14, 1649-1657.
54. Yang, C. H.; Gonzalez-Angulo, A. M.; Reuben, J. M.; Booser, D. J.; Pusztai, L.; Krishnamurthy, S.; Esseltine, D.; Stec, J.; Broglio, K. R.; Islam, R.; Hortobagyi, G. N.; Cristofanilli, M. Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann. Oncol. 2006, 17, 813-817.
55. Engel, R. H.; Brown, J. A.; Von Roenn, J. H.; O'Regan, R. M.; Bergan, R.; Badve, S.; Rademaker, A.; Gradishar, W. J. A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest. 2007, 25, 733-737.
56. Wickstrom, M.; Danielsson, K.; Rickardson, L.; Gullbo, J.; Nygren, P.; Isaksson, A.; Larsson, R.; Lovborg, H. Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients. Biochem. Pharmacol. 2007, 73, 25-33.
57. Lovborg, H.; Oberg, F.; Rickardson, L.; Gullbo, J.; Nygren, P.; Larsson, R. Inhibition of proteasome activity, nuclear factor-B translocation and cell survival by the antialcoholism drug disulfiram. Int. J. Cancer 2006, 118, 1577-1580.
58. Cvek, B.; Dvorak, Z. Targeting of nuclear factor-B and proteasome by dithiocarbamate complexes with metals. Curr. Pharm. Des. 2007, 13, 3155-3167.
59. Cvek, B.; Dvorak, Z. The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor? Drug Discov. Today 2008, 13, 716-722.
60. Tisato, F.; Marzano, C.; Porchia, M.; Pellei, M.; Santini, C. Copper in diseases and treatments, and copper-based anticancer strategies. Med. Res. Rev. 2010, in press.
61. Ambroggio, X. I.; Rees, D. C.; Deshaies, R. J. JAMM: a metalloprotease-like zinc site in the proteasome and signalosome. PLoS Biol. 2004, 2, 113-119.
62. Cvek, B.; Milacic, V.; Taraba, J.; Dou, Q. P. Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells. J. Med. Chem. 2008, 51, 6256-6258.
63. Gallery, M.; Blank, J. L.; Lin, Y.; Gutierrez, J. A.; Pulido, J. C.; Rappoli, D.; Badola, S.; Rolfe, M.; Macbeth, K. J. The JAMM motif of human deubiquitinase Poh1 is essential for cell viability. Mol. Cancer Ther. 2007, 6, 262-268.
64. Adler, A. S.; Littlepage, L. E.; Lin, M.; Kawahara, T. L.; Wong, D. J.; Werb, Z.; Chang, H. Y. CSN5 isopeptidase activity links COP9 signalosome activation to breast cancer progression. Cancer Res. 2008, 68, 506-515.
65. Cvek, B. Antabuse (disulfiram) as a pilot case of non-profit drug. Int. J. Cancer 2010, 127, 2486.